Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients

AIDS

Volumn 28, Issue 9, 2014, Pages 1279-1287

  Macías, Juan ^a   González, Juan ^b   Tural, Cristina ^c   Ortega González, Enrique ^d   Pulido, Federico ^e   Rubio, Rafael ^e   Cifuentes, Celia ^a   Díaz Menéndez, Marta ^b   Jou, Antoni ^c   Rubio, Purificación ^d   Burgos, Ángel ^f   Pineda, Juan A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f ABBVIE INC   (United States)

Author keywords

Controlled attenuation parameter; Hepatic steatosis; HIV

Indexed keywords

ABACAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZALCITABINE; ZIDOVUDINE; BIOLOGICAL MARKER;

ADULT; ARTICLE; CLINICAL EXAMINATION; CONTROLLED ATTENUATION PARAMETER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC PROCEDURE; DISEASE TRANSMISSION; ELASTOGRAPHY; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MIXED INFECTION; PARAMETERS; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; BODY MASS; COMPLICATION; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY;

ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84922481098     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000248     Document Type: Article

References (34)

1. Pineda JA, García-García JA, Aguilar Guisado M, Ríos-Villegas MJ, Ruiz-Morales J, Rivero A, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007; 46:622-630.
2. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387-1396.
3. Mallet VO, Sultanik PS, Vallet-Pichard A, Pol S. HIV-associated obliterative portopathy (HIV-OP) underlies cryptogenic liver disease in HIV-seropositive patients. HIV Med 2010; 11:540-541.
4. Maida I, Núñez M, Ríos MJ, Martín-Carbonero L, Sotgiu G, Toro C, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006; 42:177-182.
5. Merchante N, Pérez-Camacho I, Mira JA, Rivero A, Macías J, Camacho A, et al. Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. Antiviral Ther 2010; 15:753-763.
6. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. Hepatology 2010; 52:71-78.
7. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51:1972-2198.
8. Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19:585-592.
9. McGovern BH, Ditelberg JS, Taylor LE, Gandhi RT, Christopoulos KA, Chapman S, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006; 43:365-372.
10. Pascual Pareja JF, Camino A, Larrauri J, López-Diéguez M, Montes ML, González-García J, et al. Factors associated with hepatic steatosis in human immunodeficiency virus and hepatits C virus coinfected patients. Med Clin (Barc) 2009; 132:208-213.
11. Woreta TA, Sutcliffe CG, Mehta SH, Brown TT, Higgins Y, Thomas DL, et al. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology 2011; 140:809-817.
12. Macías J, Berenguer J, Japón MA, Girón-González JA, Rivero A, López-Cortés LF, et al. Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. Hepatology 2012; 56:1261-1270.
13. Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol 2006; 44:1026-1032.
14. Crum-Cianflone N, Dilay A, Collins G, Asher D, Campin R, Medina S, et al. Nonalcoholic fatty liver disease among HIVinfected persons. J Acquir Immune Defic Syndr 2009; 50:464-473.
15. Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, Ligabue G, et al. Nonalcoholic fatty liver disease in HIVinfected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008; 47:250-257.
16. Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE-guided ultrasonic attenuation measurement for estimating hepatic steatosis. Ultrasound Med Biol 2010; 36:1825-1835.
17. Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): a novel tool for the noninvasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 2012; 36:13-20.
18. De Lédinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Noninvasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012; 32:911-918.
19. Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012; 32:902-910.
20. Friedrich-Rust M, Romen D, Vermehren J, Kriener S, Sadet D, Herrmann E, et al. Acoustic radiation force impulse-imaging and transient elastography for noninvasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 2012; 81:e325-e331.
21. Vergara S, Macías J, Rivero A, Gutiérrez-Valencia A, González-Serrano M, Merino D, et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007; 45:969-974.
22. Castera L, Forns X, Alberti A. Noninvasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48:835-847.
23. Bonnet E, Delpierre C, Sommet A, Marion-Latard F, Hervé R, Aquilina C, et al. Total body composition by DXA of 241 HIVnegative men and 162 HIV-infected men. J Clin Densitom 2005; 8:287-292.
24. Mottin CC, Moretto M, Padoin AV, Swarowsky AM, Toneto MG, Glock L, Repetto G. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 2004; 14:635-637.
25. Ingiliz P, Valantin MA, Duvivier C, Medja F, Dominguez S, Charlotte F, et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009; 49:436-442.
26. Nguyen NT, Magno CP, Lane KT, Hinojosa MW, Lane JS. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg 2008; 207:928-934.
27. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34:274-285.
28. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115:1343-1351.
29. Maagaard A, Kvale D. Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms? J Antimicrob Chemother 2009; 64:901-909.
30. Venhoff N, Setzer B, Melkaoui K, Walker UA. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Ther 2007; 12:1075-1085.
31. Blas-García A, Apostolova N, Ballesteros D, Monleón D, Morales JM, Rocha M, et al. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 2010; 52:115-125.
32. McComsey GA, Kitch D, Sax PE, Monleón D, Morales JM, Rocha M, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir or efavirenz: ACTG Study A5224s. Clin Infect Dis 2011; 53:185-196.
33. Stanley TL, Grinspoon SK. Body composition and metabolic changes in HIV-infected patients. J Infect Dis 2012; 205 (Suppl 3):S383-S390.
34. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2011; 33:525-540.